**Afatinib: A Targeted Therapy for Non-Small Cell Lung Cancer (NSCLC)**

**Definition:**  

Afatinib is an oral, irreversible tyrosine kinase inhibitor (TKI) designed to target and block specific mutations in the epidermal growth factor receptor (EGFR). It is a second-generation EGFR TKI, offering a more comprehensive inhibition of EGFR family proteins compared to first-generation inhibitors.

**Function:**  

Afatinib works by binding to and inhibiting the activity of mutated EGFR proteins, which are often overactive in certain types of NSCLC. By blocking these signals, it prevents cancer cell growth and proliferation, offering a targeted approach to treatment with fewer side effects compared to traditional chemotherapy.

**Applications:**  

Afatinib is primarily used for the treatment of patients with advanced or metastatic NSCLC who have specific EGFR mutations, such as exon 19 deletions or exon 21 (L858R) substitutions. It is also approved for use in squamous cell carcinoma of the lung following platinum-based chemotherapy. Its targeted mechanism makes it a key option in personalized cancer therapy.